|
CNS Clinical Trials: World Market Prospects 2011-2026Übersetzung: CNS (gesamte Neurowissenschaften) Klinische Studien: Marktaussichten weltweit 2011-2026
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following advantages: Receive our new report quickly, giving you the answers you need Our new study can benefit everybody interested in the CNS research, development and commercialisation sectors. You will see where the CNS sector is heading, assessing the opportunities, requirements and challenges there. You will find answers and trends - we aim to save you time and aid your decisions. Order our report now, making sure you don't miss out. Please let us help today. 165 seiten | |||||||||||
| Inhalt der Studie: |
How will the CNS clinical trials sector develop from 2010, and where can you find the greatest opportunities there? Our new report shows you prospects for revenue growth worldwide, with contract resea.....
How will the CNS clinical trials sector develop from 2010, and where can you find the greatest opportunities there? Our new report shows you prospects for revenue growth worldwide, with contract research providers and sponsors of CNS clinical trials analysed. Investment in R&D for central nervous system disorders comes second only to that of oncology. We show how you could make gains in the CNS sector, especially for treating neurological disorders. You can assess the potential of the industry and market now. Our new study provides revenue forecasting with discussions of commercial drivers and restraints. It is your connection to the organisations, ideas and activities that are shaping the CNS trials sector. You can order our report now, staying ahead in your work. What opportunities, challenges and requirements are there for companies developing CNS drugs? What role will CROs play in the expansion of the market? What revenue growth can the CNS clinical research sector achieve from 2010 to 2021? Our report provides data on the current and future of the CNS clinical trials industry and market. We cover the overall world market and leading national markets, giving you the hard data and answers you need. This decade, faster patient recruitment, improved assessments and important R&D developments will characterise industry leaders in CNS disorders. Companies will adapt to new trial designs and imaging technologies. Read our study to find out how. We show you where the sector is heading from 2010 to 2021 - the events, technology and revenues. You can benefit by ordering now, staying ahead. Analysis and expert opinion to aid your work - so you won't be left behind Our new report provides you with revenue forecasts, market share analyses, R&D developments and expert opinion. We include 92 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead with our report, benefiting your analyses and commercial ideas: • Time-saving access to present and future industry trends, harnessing years of analytical knowledge • Data and discussions to benefit your market research, analyses and decision making • Tables, charts and lists to help make your reports, proposals, meetings, presentations and selling pitches more influential. Report Highlights Companies Listed Abbott AbC.R.O. Alcon Laboratories Allergan Alliance Research Group Allphase Clinical Research Apollo Hospitals Group Aptuit Association of Clinical Research Organizations (ACRO) [US] Astellas Pharma AstraZeneca Averion International Baxter Healthcare Bayer Behavioral & Medical Research BioClinica Biogen Idec BioScape Biotrofix Boehringer Ingelheim Bristol-Myers Squibb Caprion Proteomics Cerebricon Charles River Laboratories Chiltern International Clinica Research Foundation EEU ClinInvent Research CMIC Co CNS Clinical Trials (Comprehensive NeuroScience subsidiary) CNS Healthcare CNS Network CNS Response CNS Vital Signs CNS-CRO Cogtest (subsidiary of The Cognition Group) Columbia University (US) Comprehensive NeuroScience Council for International Organizations of Medical Sciences (CIOMS) Covance Dr. Reddy's Laboratories Eisai Ekam Imaging Elan Eli Lilly Encorium eResearch Technology (ERT) European Federation of Pharmaceutical Industries and Associations (EFPIA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Forenap Pharma Forest Laboratories Friedrich Miescher Institute for Biomedical Research (Switzerland) GE Healthcare Genstar Capital Genzyme Global CNS Research GlaxoSmithKline (GSK) Guy's and St Thomas' NHS Foundation Trust (UK) i3 Research ICON INC Research Institute of Medicine (US) International Conference on Harmonisation (ICH) Janssen Alzheimer Immunotherapy Janssen Korea Janssen Pharmaceutica (Belgium) Janssen Pharmaceutical (Japan) Janssen-Cilag Janssen-Ortho Japan Pharmaceutical Manufacturers Association (JPMA) JLL Partners Johnson & Johnson Pharmaceutical Research and Development Johnson & Johnson (J&J) Jubilant Biosys (subsidiary of Jubilant Life Sciences) Jubilant Life Sciences KCR Kendle Key Obs King's College London Lifetree Clinical Research Lundbeck MakroCare Massachusetts General Hospital Massachusetts Institute of Technology MD Biosciences MedAvante Medivation Merck KGaA Merck & Co Miicro Ministry of Health, Labour and Welfare (MHLW) Molecular Neuroimaging MS Therapeutics Myriad Genetics National Institute of Aging (US) National Institute of Mental Health (NIMH) [US] National Institutes of Health (NIH) [US] National Library of Medicine (US) Neurodigitech NEUROFIT Neuroimage NeuroSearch Novartis Noven Pharmaceuticals Octapharma Omega CRO Omnicare Clinical Research Ortho-McNeil Janssen Pharmaceutical Otsuka Paragon Biomedical Parexel Patient-Centered Outcomes Research Institute (PCORI) Perceptive Informatics Pfizer Pharmaceutical Research and Manufacturers of America (PhRMA) PharmaNet Pharmidex PPD PRA International Premier Research Prevalere Life Sciences Pronexus Analytical Prosensa Therapeutics Psychmed (subsidiary of The Cognition Group) PsychoGenics QCTR Quintiles Ranbaxy Laboratories Roche sanofi-aventis Schering-Plough Shire Stirling University (UK) Takeda Tangent Data Targacept Teva The Cognition Group Timaq Medical Imaging Tufts Center for the Study of Drug Development UCB United BioSource Corp (UBC) United Nations Educational, Scientific and Cultural Organization (UNESCO) University of Michigan (US) University of Prince Edward Island (Canada) Veeda Clinical Research Veeda Laboratories (former subsidiary of Veeda Clinical Research Group) World Health Organization (WHO) Wyeth (now part of Pfizer [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Overview of Findings 1.2 Chapter Breakdown 1.3 Research Methods 1.4 Format of the Report 1.4.1 Market Growth or Rising Costs? 2. CNS Clinical Trials: An Introduction 2.1 Central Nervous System Disorders 2.1.1 The Central Nervous System (CNS) 2.1.2 Common CNS Disorders 2.1.3 Causes of CNS Disorders 2.1.4 The CNS Drug Market 2009 2.2 Clinical Trials 2.2.1 A Brief History of Clinical Trials 2.2.1.1 The Nuremburg Code and the Declaration of Helsinki 2.2.1.2 Council for International Organizations of Medical Sciences (CIOMS) 2.2.1.3 Good Clinical Practice 2.3 Phases of Clinical Trials 2.3.1 Phase I Trials 2.3.2 Phase II Trials 2.3.3 Phase III Trials 2.3.4 Phase IV Trials: Post-Marketing Surveillance 2.4 Clinical Research Outsourcing 3. Global CNS Clinical Trials Market 2010-2026 3.1 The Global CNS Clinical Trials Market in 2010 3.1.1 CNS Clinical Trials in 2010, by Phase 3.1.2 Value of the CNS Clinical Trials Market in 2010 3.2 Leading Sponsors of CNS Clinical Trials in 2010 3.2.1 GSK 3.2.2 Pfizer 3.2.3 Novartis 3.2.4 AstraZeneca 3.2.5 J&J 3.3 CNS Clinical Trials: Market Forecast 2011-2026 3.3.1 Significant Unmet Needs to Drive Growth 3.3.2 Increasing Emphasis on Late-Stage Trials 3.3.3 CNS Clinical Trials Market: 2011-2016 3.3.4 CNS Clinical Trials Market: 2016-2021 3.3.5 CNS Clinical Trials Market: 2021-2026 3.4 In-house vs. CROs 3.4.1 Clinical Research Outsourcing 3.4.2 CNS CRO Market to Grow from 2011 4. Leading National Market Forecasts 2011-2026 4.1 Regional CNS Clinical Trials Markets 2010 4.2 Regional CNS Clinical Trials Markets: Forecast 2011-2026 4.3 US and Canada 4.4 Europe 4.4.1 Europe: Half Emerging, Half Established 4.4.2 Western Europe 4.4.2.1 Market Forecast 2011-2026 4.5 BRIC Nations 4.6 Brazil 4.6.1 CNS Clinical Trials in Latin America 4.7 Russia 4.8 India 4.9 China 4.9.1 Chinese Interest in CNS Disorders Set to Increase 4.10 Other Emerging Markets 4.10.1 CEE 4.10.2 South East Asia 5. Leading Companies Providing CRO Services for CNS Clinical Trials 5.1 Quintiles 5.1.1 Expertise in CNS Clinical Trials 5.1.2 Recent Developments and Growth Strategies 5.2 Covance 5.2.1 Financial Performance 2009 5.2.2 Covance CNS Experience 5.2.3 Industry Partnerships 5.3 Pharmaceutical Product Development (PPD) 5.3.1 Financial Performance 2009 5.3.2 CNS: Over 330 Trials in Five Years 5.3.3 Expanding in Eastern Europe 5.3.4 Vaccines and Biologics 5.4 Charles River Laboratories 5.4.1 Financial Performance 2009 5.4.2 Interest in CNS Development 5.5 Parexel 5.5.1 Financial Performance 2009 5.5.2 Experts in CNS Clinical Trials 5.6 ICON 5.6.1 Financial Performance 2009 5.6.2 Ten Years of CNS Experience 5.6.3 Expanding into Biomarkers and Imaging 5.7 Kendle 5.7.1 Financial Performance 2009 5.7.2 CNS Clinical Trial Capabilities 5.8 PRA International 5.8.1 CNS Clinical Trial Experience 5.9 PharmaNet Development Group 5.9.1 PharmaNet Neuroscience 5.9.2 Emerging Market Expansion 5.10 CNS Specialists 5.11 CROs Specialising in Pre-clinical CNS Services 5.11.1 Biotrofix 5.11.2 CNS-CRO 5.12 CNS Patient Recruitment Services 5.12.1 QCTR 5.12.2 Alliance Research Group 5.13 Early-stage CNS CROs 5.13.1 CNS Network 5.13.2 Forenap 5.13.3 Lifetree Clinical Research 5.14 Some Companies Specialise in All Development Phases 5.14.1 Tangent Data 5.14.2 Comprehensive NeuroScience (CNS) 5.15 Imaging and Testing for CNS Trials 5.15.1 Neuroimage 5.15.2 Miicro 5.15.3 Cogtest 6. Industry Trends from 2011 6.1 SWOT Chart for CNS Trial Sponsors: 2010-2026 6.1.1 High Cost, Low Success 6.1.2 Money-Saving Opportunities 6.1.3 High Placebo Response Rates 6.2 SWOT Chart for CROs in the CNS Sector: 2010-2026 6.2.1 More-efficient Trials 6.2.2 Big Pharma M&A to Boost CRO Growth 6.2.2.1 Strategic Partnering 6.2.3 Patient Recruitment and Enrolment 6.3 Suicidality 6.3.1 The Columbia Suicide Severity Rating Scale (C-SSRS) 6.3.2 Man vs. Machine 6.4 Alternative Trial Design 6.4.1 Delayed-Start Trials 6.4.2 Challenges with Delayed-start Trials 6.4.3 Case Study: The ADAGIO Trial 6.4.4 Adaptive Clinical Trials 6.5 Neuroimaging 6.5.1 Neuroimaging Biomarkers 6.5.2 Neuroimaging and Future Drug Development 6.5.3 Alzheimer's Disease 6.5.4 Alzheimer's Disease Neuroimaging Initiative 6.6 CNS Target Compounds Are Changing 6.6.1 Neuroprotective Drugs 6.6.2 Biologics & Biosimilars 6.7 Benefits and Challenges to Outsourcing CNS Trials 6.7.1 Large Patient Populations 6.7.2 Genetic Variations 6.8 Challenges Faced by Large Pharma Companies in CNS R&D 6.9 Animal Models Must Be Improved Upon 7. Expert Opinion 7.1 Professor Alan Palmer, Chief Scientific Officer and Co-founder, MS Therapeutics 7.1.1 Neuroimaging and CNS Drug Development 7.1.2 Delayed-start Trials for CNS Diseases 7.1.3 Patient Recruitment in CNS Clinical Trials 7.1.4 Changing Priorities in CNS Drug Development 7.1.5 Therapeutic Areas That Will See Increased Investment 7.1.6 Threats to CNS Drug Development and Clinical Trials 7.2 Dr Amir Kalali, Vice President, Medical and Scientific Services and Global Therapeutic Group Leader, CNS at Quintiles 7.2.1 Challenges in Neuroimaging Biomarkers 7.2.2 Placebo Problems in CNS Clinical Trials 7.2.3 CROs in the CNS Clinical Trials Market 7.2.4 Failure Rate in CNS R&D 7.2.5 Big Pharma and CNS R&D 7.2.6 Globalisation 7.2.7 Challenges in CNS Clinical Trials 8. Conclusions 8.1 There Will Be Growth Throughout the Period 8.1.1 Unmet Needs to Drive Growth 8.2 CROs Will Play a Larger Role in the Market 8.3 Increasing Use of Neuroimaging 8.4 Emerging Markets to Drive Growth 8.4.1 India and China [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 World CNS Disease Drug Market, 2009 Table 2.2 Members of the ICH, 2010 Table 3.1 CNS Clinical Trials by Phase, 2010 Table 3.2 CNS Clinical Trials Market, 2010 Table 3.3 Top 25 Big Pharma Sponsors of CNS Clinical Trials, 2010 Table 3.4 GSK's Neuroscience Pipeline, February 2010 Table 3.5 Pfizer's Neuroscience Pipeline, September 2010 Table 3.6 Novartis CNS Clinical Trials Enrolling in November 2010 Table 3.7 AstraZeneca's Neuroscience Pipeline, 2010 Table 3.8 Janssen-Sponsored Clinical Trials, 2010 Table 3.9 World CNS Clinical Trials Market Forecast, 2010-2018 Table 3.10 World CNS Clinical Trials Market Forecast, 2018-2026 Table 3.11 CNS Clinical Trials Drivers and Restraints, 2011-2026 Table 3.12 CRO and In-house Market Shares, 2010-2026 Table 3.13 CNS CRO Market Drivers and Restraints, 2011-2026 Table 4.1 CNS Clinical Trials Market by Region, 2010 Table 4.2 CNS Clinical Trials Market: National Forecasts, 2010-2018 Table 4.3 CNS Clinical Trials Market: National Forecasts, 2018-2026 Table 4.4 CNS Clinical Trials Market Regional Shares, 2010-2026 Table 4.5 CNS Clinical Trials Registered in US and Canada by Phase, 2010 Table 4.6 US and Canadian Market Drivers and Restraints, 2011-2026 Table 4.7 European CNS Clinical Trials by Phase, 2010 Table 4.8 EU Membership Status of CEE Countries, 2010 Table 4.9 CNS Clinical Trials in Selected Western European Countries by Phase, 2010 Table 4.10 Western Europe Market Drivers and Restraints, 2011-2026 Table 4.11 Relative Cost of Conducting Clinical Trials in Western Europe, 2010 Table 4.12 CNS Clinical Trials in BRIC Nations, 2010 Table 4.13 Latin American Market Benefits and Challenges, 2011-2026 Table 4.14 Russian Market Drivers and Restraints, 2011-2026 Table 4.15 Indian Market Benefits and Challenges, 2011-2026 Table 4.16 Chinese Market Benefits and Challenges, 2011-2026 Table 4.17 CNS Disorder Prevalence in South East Asia, 2010 Table 5.1 Number of CNS Clinical Trials Performed by Company, 1990-2010 Table 5.2 CROs Offering CNS Services Not Discussed in This Report, 2010 Table 5.3 Covance Sales by Market Segment, 2009 Table 5.4 PPD Sales by Market Segment, 2009 Table 5.5 Parexel Sales by Market Segment, 2009 Table 5.6 ICON Sales by Region, 2009 Table 5.7 Kendle Sales by Market Segment, 2009 Table 5.8 Kendle Sales by Region, 2009 Table 5.9 CNS Specialist CROs Not Discussed in This Report, 2010 Table 6.1 SWOT Chart for CNS Clinical Trial Sponsors, 2011-2026 Table 6.2 SWOT Chart for CROs Conducting CNS Clinical Trials, 2011-2026 Table 6.3 C-CASA Levels of Suicidality, 2010 Table 6.4 Some Companies Offering Neuroimaging Services for CNS Clinical Trials, 2010 Table 6.5 Levels of Biomarker, 2010 Table 6.6 Selected Treatments Targeting Amyloid-?, 2010 Table 8.1 CNS Clinical Trials Market Forecast, 2010-2026 Table 8.2 CNS Clinical Trials Market by Region, 2010-2026 Figure 2.1 World CNS Diseases Drug Market, 2009 Figure 2.2 The Drug Development Process, 2010 Figure 3.1 CNS Clinical Trials by Phase, 2010 Figure 3.2 CNS Clinical Trials Market, 2010 Figure 3.3 Top 25 Big Pharma Sponsors of CNS Clinical Trials, 2010 Figure 3.4 GSK's Neuroscience Pipeline, February 2010 Figure 3.5 Pfizer's Neuroscience Pipeline, September 2010 Figure 3.6 AstraZeneca's Neuroscience Pipeline, 2010 Figure 3.7 World CNS Clinical Trials Market, 2010-2026 Figure 3.8 World CNS Clinical Trials Market, 2016 Figure 3.9 World CNS Clinical Trials Market, 2021 Figure 3.10 World CNS Clinical Trials Market, 2026 Figure 4.1 CNS Clinical Trials Market by Region, 2010 Figure 4.2 CNS Clinical Trials Market by Region, 2016 Figure 4.3 CNS Clinical Trials Market by Region, 2021 Figure 4.4 CNS Clinical Trials Market by Region, 2026 Figure 4.5 US and Canada CNS Trials Split by Country, 2010 Figure 4.6 US and Canada CNS Trials by Phase, 2010 Figure 4.7 US and Canada: CNS Clinical Trials Market, 2010-2026 Figure 4.8 European CNS Trials by Phase, 2010 Figure 4.9 CNS Clinical Trials in Selected Western European Countries, 2010 Figure 4.10 CNS Clinical Trials in Selected Western European Countries by Phase, 2010 Figure 4.11 Selected Western European Countries: CNS Clinical Trials Market, 2010-2026 Figure 4.12 CNS Clinical Trials in BRIC Countries, 2010 Figure 4.13 CNS Clinical Trials in BRIC Countries by Phase, 2010 Figure 4.14 BRIC National CNS Clinical Trials Markets, 2010-2026 Figure 4.15 CNS Clinical Trials in Brazil by Phase, 2010 Figure 4.16 CNS Clinical Trials in Russia by Phase, 2010 Figure 4.17 CNS Clinical Trials in India by Phase, 2010 Figure 4.18 CNS Clinical Trials in China by Phase, 2010 Figure 4.19 Other CNS Clinical Trials Markets, 2010-2026 Figure 4.20 CNS Disorder Prevalence in South East Asia, 2010 Figure 5.1 Number of CNS Clinical Trials Performed by Company, 1990-2010 Figure 5.2 Covance Sales by Market Segment, 2009 Figure 5.3 Covance Sales by Region, 2009 Figure 5.4 PPD Sales by Market Segment, 2009 Figure 5.5 Charles River Laboratories Sales by Market Segment, 2009 Figure 5.6 Parexel Sales by Market Segment, 2009 Figure 5.7 ICON Sales by Region, 2009 Figure 5.8 Kendle Sales by Market Segment, 2009 Figure 5.9 Kendle Sales by Region, 2009 Figure 6.1 Suicidality and the FDA, 2003-2008 Figure 6.2 The Delayed-start Trial Design [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
